Article
Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.
Antimicrobial agents and chemotherapy - 1 Oct 2000
Jones M E, Staples A M, Critchley I, Thornsberry C, Heinze P, Engler H D, Sahm D F
Abstract excerpt
To benchmark the activity of moxifloxacin (a newer fluoroquinolone), a U.S. study comprising 16,141 contemporary isolates of Streptococcus pneumoniae (5,640), Haemophilus influenzae (6,583), and Moraxella catarrhalis (3,648) referred from 377 institutions during 1998 is described. For S. pneumoniae the modal MIC and MIC at which 90% of the isolates were inhibited (MIC(90)) for moxifloxacin were 0.12 and 0.25...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.